Therapies based on antibodies and inhibitors targeting HER2 have revolutionized breast cancer treatment wherein the pre-therapeutic invasive biopsy for histopathological confirmation of sufficient HER2 expression (e.g., HercepTest®) for the patient selection and prediction of response is conducted [161,163,167,168,169,170]. This evidence concerns the gene ERBB2 and breast cancer.